These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 15753225)
1. Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda. Leopold JA; Antman EM Circulation; 2005 Mar; 111(9):1097-9. PubMed ID: 15753225 [No Abstract] [Full Text] [Related]
2. Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting. Steinhubl SR; Topol EJ J Thromb Thrombolysis; 1999 Jun; 7(3):227-31. PubMed ID: 10373712 [No Abstract] [Full Text] [Related]
3. Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999. McCullough PA; Marks KR J Thromb Thrombolysis; 1999 Jun; 7(3):233-9. PubMed ID: 10373716 [No Abstract] [Full Text] [Related]
4. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Gurbel PA; Bliden KP; Zaman KA; Yoho JA; Hayes KM; Tantry US Circulation; 2005 Mar; 111(9):1153-9. PubMed ID: 15738352 [TBL] [Abstract][Full Text] [Related]
7. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173 [TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Rubboli A; Milandri M; Castelvetri C; Cosmi B Cardiology; 2005; 104(2):101-6. PubMed ID: 16020950 [TBL] [Abstract][Full Text] [Related]
9. Dual oral antiplatelet therapy and unplanned surgery: possible role for intravenous platelet glycoprotein receptor inhibitors. Bollati M; Giraudi E; Moretti C; Millesimo G; Sciuto F; Omedè P; Biondi Zoccai G; Sheiban I J Cardiovasc Med (Hagerstown); 2011 Sep; 12(9):673-4. PubMed ID: 21796059 [No Abstract] [Full Text] [Related]
11. [New antiaggregants and their importance for the practitioner]. Tsakiris DA Ther Umsch; 2003 Jan; 60(1):24-6. PubMed ID: 12638474 [TBL] [Abstract][Full Text] [Related]
12. Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot Genous trial. Sangiorgi GM; Morice MC; Bramucci E; Ferlini M; Grinfeld L; Petronio AS; Pierli C; Iadanza A; Biondi-Zoccai G; Colombo A EuroIntervention; 2011 Nov; 7(7):813-9. PubMed ID: 22082577 [TBL] [Abstract][Full Text] [Related]
13. [Clopidogrel should be added to aspirin for at least 1 year after percutaneous coronary interventions (CREDO) while before them its loading dose can reach 600mg (ISAR-COOL)]. Gratsianskiĭ NA Kardiologiia; 2003; 43(5):71-3. PubMed ID: 12942928 [No Abstract] [Full Text] [Related]
14. Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy. Denardo SJ; Davis KE; Tcheng JE Am Heart J; 2005 Jan; 149(1):138-44. PubMed ID: 15660045 [TBL] [Abstract][Full Text] [Related]
15. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470 [TBL] [Abstract][Full Text] [Related]
16. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial. Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE; Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469 [TBL] [Abstract][Full Text] [Related]
17. Optimal antiplatelet therapy during percutaneous coronary interventions includes glycoprotein IIb/IIIa inhibitors just eliminate the infusion. Mahmud E; Prasad A J Am Coll Cardiol; 2009 Mar; 53(10):846-8. PubMed ID: 19264240 [No Abstract] [Full Text] [Related]
18. Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY). Rangé G; Yayehd K; Belle L; Thuaire C; Richard P; Cazaux P; Barbou F; Köning R; Chassaing S; Teiger E; Berthier R; Decomis MP; Claudel JP; Delarche N; Brunel P; De Poli F; Dupouy P; Beygui F; Albert F; Collet JP; Montalescot G; Arch Cardiovasc Dis; 2014 Apr; 107(4):225-35. PubMed ID: 24794216 [TBL] [Abstract][Full Text] [Related]
19. Another view on prasugrel. Calatzis A Thromb Haemost; 2009 Jan; 101(1):12-3. PubMed ID: 19132183 [No Abstract] [Full Text] [Related]